Based on these observations, cenicriviroc (CVC), a dual CCR2 and CCR5 antagonist, is expected to improve NASH and has been tested in clinical trials in patients with NASH-associated liver fibrosis [21,22]. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.